Secure Point Technologies Inc (fka IMSCQ)

[Entendance]

Implant Sciences' QS-B220 Successfully Passes QT&E Portion of Checkpoint and Checked Baggage Qualification

QS-B220 is the first ETD with non-radioactive source to successfully complete the test and evaluation phase at TSA's Transportation Systems Integration Facility

http://tinyurl.com/nse92vy

WILMINGTON, Mass., Feb. 27, 2014 /PRNewswire/ -- Implant Sciences Corporation (OTCQB:IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, announced today that its QS-B220 desktop explosives trace detection system has successfully completed and passed testing requirements of the Qualification Testing and Evaluation (QT&E) portion of the Transportation Security Administration's (TSA) Explosive Trace Detection (ETD) qualification test at the Transportation Systems Integration Facility (TSIF).

TSA's state-of-the-art TSIF, located at Ronald Reagan Washington National Airport, is where new screening technologies are tested before they are deployed to airports around the country. The facility provides an operational airport environment where TSA evaluates the technology by its concepts of operation, measures of performance, and measures of effectiveness.

In July 2013, the QS-B220 successfully completed the first step of QT&E, called Independent Testing and Evaluation (IT&E). QS-B220 has since passed the second step of QT&E at the TSIF, thereby fulfilling another important step towards qualifying the QS-B220 by the Transportation Security Administration and for use in major airports all across the US.

"Evaluation of our QS-B220 was a very important achievement that demonstrates the benefits of our ETD technology in action. The QS-B220 provides superior detection capabilities, a non-radioactive source, and operational and cost efficiencies that can deliver benefits at airport security checkpoints each year. The combination of enhanced performance and operational capabilities of the QS-B220 truly define the new standard of trace detection," stated Glenn D. Bolduc, Implant Sciences' President and CEO.

"Successfully completing QT&E brings us another step closer to completing TSA's Qualified Product List process, and we are confident that the QS-B220 will meet the remaining stringent testing requirements," added Dr. Darryl Jones, Vice President of Sales and Marketing at Implant Sciences.